BIOLASE, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Concentrations

Concentrations

12 Months Ended

Dec. 31, 2015

Risks And Uncertainties [Abstract]

Concentrations

NOTE 10 — CONCENTRATIONS

Revenue from the Company’s products for the years ended December 31, 2015, 2014 and 2013 are as follows:

	Years Ended December 31,
	2015			2014			2013
Laser systems		67.5	%		61.9	%		68.6	%
Imaging systems		4.6	%		9.0	%		8.2	%
Consumables and other		14.2	%		13.7	%		11.5	%
Services		13.3	%		15.1	%		11.3	%
License fees and royalties		0.4	%		0.3	%		0.4	%
Total revenue		100.0	%		100.0	%		100.0	%

Approximately 3%, 6%, and 5% of the Company’s revenue in 2015, 2014, and 2013, respectively, was generated through sales to Henry Schein, Inc. worldwide.

The Company maintains its cash and cash equivalent accounts with established commercial banks. Such cash deposits periodically exceed the Federal Deposit Insurance Corporation insured limit.

No individual customer represented more than 10% of the Company’s accounts receivable at December 31, 2015 and 2014.

The Company currently purchases certain key components of its products from single suppliers. Although there are a limited number of manufacturers of these key components, management believes that other suppliers could provide similar key components on comparable terms. A change in suppliers, however, could cause delays in manufacturing and a possible loss of sales, which could adversely affect the Company’s business, results of operations and financial condition.